NASDAQ:YMAB

Y-mAbs Therapeutics (YMAB) News Today

$8.17

+0.04 (+0.49%)

(As of 06/9/2023 ET)

Compare

Today's Range: $8.00
▼
$8.66
50-Day Range: $5.68
▼
$10.34
52-Week Range: $2.70
▼
$20.48

Volume: 257,093 shs
Average Volume: 314,901 shs
Market Capitalization: $356.87 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.67

Get Y-mAbs Therapeutics News Delivered to You Automatically

YMAB Media Mentions By Week

YMAB Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

YMAB
News Sentiment
▼
0.88

0.90
▲
Average
Medical
News Sentiment

YMAB News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

YMAB Articles
This Week
▼
4

4
▲
YMAB Articles
Average Week

Source

Source	Headline
	Canaccord Genuity Reiterates Y-Mabs Therapeutics (YMAB) Buy Recommendation msn.com - June 8 at 1:17 AM
	Canaccord Genuity Sticks to Their Buy Rating for Y-Mabs Therapeutics (YMAB) markets.businessinsider.com - June 7 at 3:15 PM
	99,160 Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Acquired by GSA Capital Partners LLP marketbeat.com - June 7 at 7:27 AM
	Y-mAbs Therapeutics (NASDAQ:YMAB investor three-year losses grow to 81% as the stock sheds US$53m this past week finance.yahoo.com - June 2 at 4:34 PM
	Cornercap Investment Counsel Inc. Invests $235,000 in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) marketbeat.com - June 2 at 8:26 AM
	Connor Clark & Lunn Investment Management Ltd. Purchases 127,068 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) marketbeat.com - June 1 at 6:52 AM
	Y-mAbs Announces Presentation of GD2-SADA Study at ASCO finance.yahoo.com - May 26 at 10:38 AM
	Y-mAbs Announces Presentation of Naxitamab Data at ASCO finance.yahoo.com - May 26 at 10:38 AM
	Brokerages Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Target Price at $13.13 americanbankingnews.com - May 24 at 1:36 AM
	Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil finance.yahoo.com - May 23 at 9:20 AM
	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Hold" by Brokerages marketbeat.com - May 21 at 2:34 AM
	B of A Securities Maintains Y-Mabs Therapeutics (YMAB) Neutral Recommendation msn.com - May 15 at 6:24 PM
	B of A Securities Maintains Neutral Rating for Y-mAbs Therapeutics: Here's What You Need To Know markets.businessinsider.com - May 15 at 1:24 PM
	Bank of America Securities Keeps Their Hold Rating on Y-Mabs Therapeutics (YMAB) markets.businessinsider.com - May 15 at 8:23 AM
	Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Increased to $12.00 by Analysts at Bank of America americanbankingnews.com - May 15 at 8:22 AM
	Q2 2023 Earnings Forecast for Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Issued By Wedbush americanbankingnews.com - May 14 at 1:22 AM
	New Forecasts: Here's What Analysts Think The Future Holds For Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) finance.yahoo.com - May 13 at 1:31 PM
	FY2027 Earnings Forecast for Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Issued By Wedbush americanbankingnews.com - May 13 at 6:12 AM
	Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Rating Upgraded by Wedbush americanbankingnews.com - May 13 at 2:16 AM
	Wedbush Upgrades Y-Mabs Therapeutics (YMAB) msn.com - May 12 at 8:16 AM
	Q2 2023 EPS Estimates for Y-mAbs Therapeutics, Inc. Reduced by Wedbush (NASDAQ:YMAB) marketbeat.com - May 12 at 7:39 AM
	Morgan Stanley Maintains Y-Mabs Therapeutics (YMAB) Underweight Recommendation msn.com - May 12 at 3:16 AM
	Novartis (NYSE:NVS) & Y-mAbs Therapeutics (NASDAQ:YMAB) Financial Review americanbankingnews.com - May 11 at 2:38 AM
	Y-mAbs gains as Wedbush upgrades after Q1 results msn.com - May 10 at 9:10 PM
	Analyst Upgrades Y-mAbs On Bullish Danyelza Sales Outlook, Improved Visibility markets.businessinsider.com - May 10 at 4:09 PM
	Y-mAbs Therapeutics First Quarter 2023 Earnings: Beats Expectations finance.yahoo.com - May 10 at 11:08 AM
	Q1 2023 Y-mAbs Therapeutics Inc Earnings Call finance.yahoo.com - May 10 at 6:08 AM
	Y-mAbs Therapeutics, Inc: Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance finanznachrichten.de - May 9 at 2:11 PM
	Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates finance.yahoo.com - May 8 at 11:07 PM
	Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance finance.yahoo.com - May 8 at 6:07 PM
	Y-mAbs Therapeutics (YMAB) Scheduled to Post Quarterly Earnings on Monday americanbankingnews.com - May 7 at 6:00 AM
	Preview: Y-mAbs Therapeutics's Earnings msn.com - May 5 at 5:06 PM
	Analysts Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) PT at $11.38 americanbankingnews.com - April 29 at 1:48 AM
	Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023 finance.yahoo.com - April 28 at 1:15 PM
	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest Down 28.4% in April americanbankingnews.com - April 28 at 1:22 AM
	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Sees Significant Decrease in Short Interest marketbeat.com - April 27 at 1:23 AM
	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Recommendation of "Hold" from Brokerages marketbeat.com - April 26 at 2:33 AM
	Y-mAbs Therapeutics (NASDAQ:YMAB) versus BioXcel Therapeutics (NASDAQ:BTAI) Critical Comparison americanbankingnews.com - April 23 at 2:30 AM
	Strs Ohio Grows Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) marketbeat.com - April 19 at 4:30 AM
	Y-mAbs Announces Presentation of Naxitamab data at AACR finance.yahoo.com - April 18 at 1:45 PM
	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Surges 104% Yet Its Low P/S Is No Reason For Excitement finance.yahoo.com - April 17 at 12:44 PM
	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest Update americanbankingnews.com - April 17 at 5:40 AM
	Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Lowered to $11.00 at HC Wainwright americanbankingnews.com - April 6 at 2:38 AM
	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2022 Earnings Call Transcript finance.yahoo.com - April 5 at 8:15 PM
	Wall Street Analysts Believe Y-mAbs Therapeutics, Inc. (YMAB) Could Rally 111.13%: Here's is How to Trade finance.yahoo.com - April 5 at 3:14 PM
	Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA finance.yahoo.com - April 5 at 10:14 AM
	HC Wainwright & Co. Maintains Y-mAbs Therapeutics (YMAB) Buy Recommendation msn.com - April 4 at 6:47 PM
	Y-mAbs Therapeutics (NASDAQ:YMAB) Given New $11.00 Price Target at HC Wainwright marketbeat.com - April 4 at 7:18 AM
	Canaccord Genuity Group Cuts Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $18.00 americanbankingnews.com - April 4 at 1:56 AM
	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $13.00 Average PT from Brokerages americanbankingnews.com - April 4 at 1:16 AM

Get Y-mAbs Therapeutics News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (NASDAQ:YMAB) was last updated on 6/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Y-mAbs Therapeutics (YMAB) News Today

YMAB Media Mentions By Week

YMAB Media Sentiment

YMAB News Coverage

Related Companies and Tools

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info